I'm LongbridgeAI, I can summarize articles.BriaCell Therapeutics announced a genetic engineering milestone for its Bria-MEL+ personalized melanoma vaccine candidate, advancing it toward clinical development. The technology utilizes premanufactured cell lines matched via saliva-based HLA typing to streamline production. This move expands the company's pipeline beyond its breast cancer programs, which include the pivotal Phase 3 trial for Bria-IMT and FDA-cleared Bria-PROS+. With projected U.S. melanoma cases reaching 112,000 by 2026, the development addresses a significant market need.
- BriaCell reported a genetic engineering milestone for Bria-MEL+, advancing its personalized whole-cell melanoma vaccine program toward clinical development. * Bria-MEL+ uses premanufactured cell lines selected via a saliva-based HLA match, aiming to avoid patient-by-patient manufacturing. * Development work has started to support production for potential clinical use, positioning Bria-MEL+ as an expansion beyond breast cancer programs. * The pipeline centers on Bria-IMT in a pivotal Phase 3 metastatic breast cancer trial; Bria-PROS+ received FDA clearance to begin testing. * Melanoma incidence is projected at about 112,000 U.S. cases in 2026, with 8,510 expected deaths, underscoring the target market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240730PRIMZONEFULLFEED9814741) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)